Aim To identify laboratory tests for early detection and the development of more severe illness and death in COVID-19 hospitalized patients. Methods A prospective study was done on 66 hospitalized COVID-19 patients (males: 54.5%; mean age 70.1 ± 9.6 years) who were stratified into: moderate (n=36; 54.5%), severe (n=12; 18.2%), and critically ill (n=18; 27.3%). Besides clinical findings, a wide spectrum of laboratory parameters was monitored at admission and control during the first seven days of hospitalization and used to predict progression from non-severe to severe illness and to predict the final outcome. Results Critically ill patients showed a higher control value of white blood cell count, C-reactive protein, lactate dehydrogenase, ferritin, but lower lymphocyte count and O2 saturation. Patients with fatal outcome (23; 34.85%) showed a higher control value of neutrophil, lactate dehydrogenase, ferritin, and lower lymphocyte and O2 saturation. Progression from moderate to severe or critical illness was predicted by increasing lactate dehydrogenase (95% CI 0.5803 to 0.8397;p=0.003729), increase in ferritin (95% CI 0.5288 to 0.8221;p=0.03248), and by drop in O2 saturation (95% CI 0.5498 to 0.8179;p=0.01168). A fatal outcome was predicted by increase in ferritin (95% CI 0.5059 to 0.8195;p=0.04985), as well as by drop in O2 saturation (95% CI 0.5916 to 0.8803; p=0.001861). Conclusion Increase in ferritin, and drop in O2 saturation could be the most important prognostic parameters for the development of more severe clinical illness and death in COVID-19 hospitalized patients.
Henry B, De Oliveira M, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. ClinChem Lab Med 2020:1021–8.
2
Velavan T, Meyer C. Mild versus severe CO-VID-19: laboratory markers. Int J Infect Dis 2020:304–7.
3
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 2020:687–90.
4
Dymond T. The Effects of viral infection on lymphocyte metabolism: a new perspective on disease characterization. Viral Immunol 2018:278–81.
5
Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect 2020:318–56.
6
Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, et al. Scoring systems for predicting mortality for severe patients with COVID-19. EClinicalMedicine 2020:100426.
7
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease. JAMA Intern Med 2019:934–43.
8
Deng Y, Liu W, Liu K, Fang Y, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease. Chin Med J (Engl) 2019:1261–7.
9
Lippi G, Plebani M, Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. ClinChi-MActa 2020:145–8.
10
Han Y, Zhang H, Mu S, Wei W, Tong J, Song C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY) 2020:11245–58.
11
Erez A, Shental O, Tchebiner J, Laufer-Perl M, Wasserman A, Sella T, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J 2014:439–43.
12
Henry B, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: apooled analysis. Am J Emerg Med 2020:1722–6.
13
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020:1054–62.
14
Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 2020:168.
15
Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Terracciano C. Lactate dehydrogenase and c-reactive protein as predictors of respiratory failure in COVID-19 patients. ClinChimActa 2020:135–8.
16
Netea G-BE, Rovina M, Akinosoglou N, Antoniadou K, Antonakos A, Damoraki N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020:992–1000.
17
Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia. Lab Invest 2020:794–800.
18
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. Intensive Care Med 2020:846–8.
19
Rosário C, Zandman-Goddard G, Holtz M-, E, Cruz D, Shoenfeld D, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013:185.
20
Thomas L, Thomas C. Detection of iron restriction in anaemic and non-anaemic patients: New diagnostic approaches. Eur J Haematol 2017:262–8.
21
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020:420–2.
22
Xie J, Wu W, Li S, Hu Y, Hu M, Li J, et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med 2020:1863–72.
23
Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease. Int J Infect Dis 2019:49–52.
24
Feld J, Tremblay D, Thibaud S, Kessler A. Naymagon L. Ferritin levels in patients with COVID-19: poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol 2020:773–9.
25
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet 2020:497–506.
26
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020:1708–20.
27
Zhu N, Zhang D, Wang, Yang L, Song B, Zhao J, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from patients with pneumonia in China. N Engl J Med 2019:727–33.
28
Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers 2020:616–25.
29
Tahaghoghi-Hajghorbani S, Zafari P, Masoumi E, Rajabinejad M, Jafari-Shakib R, Hasani B, et al. The role of dysregulated immune responses in CO-VID-19 pathogenesis. Virus Res 2020.
30
Rodríguez-Morales A, Macgregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global -travel and the 2019 novel coronavirus. Travel Med Infect Dis 2020:101578.
31
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020:6.
32
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020:1708–20.
33
Mehta P, Mcauley D, Brown M, Sanchez E, Tattersall R, Manson J. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020:1033–4.
34
Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020:731–3.
35
Nandy K, Salunke A, Pathak S, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. DiabetesMetabSyndr 2020:1017–25.
36
Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014:164–74.
37
Chen T, Wu D, Chen H, Yang Y, Chen D, Ma G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020:1091.
38
Pranata R, Huang I, Lukito A, Raharjo S. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J 2020:387–91.
39
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020:36.
40
Huang I, Pranata R, Lim M, Oehadian A. Alisjahbana B. C-reactive protein, procalcitonin, d-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis 2020:1753466620937175.
41
Chinese management guideline for COVID-19 (version 7.0). National Health Commission of the People’s Republic of China 2020.
42
Rukmini S. Who are India’s COVID-19 patients? 2020.
43
Mehra M, Desai S, Kuy S, Henry T, Patel A. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020:102.
44
Lipsitch M, Donnelly C, Fraser C, Blake I, Dorigatti C, Ferguson I, et al. Potential biases in estimating absolute and relative case-fatality risks during outbreaks. PLoSNegl Trop Dis 2015:3846.
45
Cummings M, Baldwin M, Abrams D, Jacobson S, Meyer B, Balough E, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020:1763–70.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
